Some new healthcare rules took effect last week offering a measure of safety and security for our diabetes patients. As part of the healthcare reform act of 2010, adult children can stay on their parents’ insurance through age 26, they cannot be dropped for pre-existing conditions and their insurance cannot …
Read More »Diabetes In Control
Newsflash: Merck Expands Patient Assistant Program
Merck expands Merck Helps, their free-of-charge vaccines and medicine program to individuals and families who earn up to 400% of the federal poverty level. To learn how your patients can benefit visit www.merckhelps.com.
Read More »Oral Medications and Diabetes
Oral Medications and Diabetes Nipro Diagnostics’ TRUEinsight® guide for patients focuses on understanding oral diabetes medications and how they help to control blood glucose levels. Understanding how oral medications work and their importance can help with patient medication compliance.
Read More »New Product: Tiniboy Lancets (36 gauge/70mm)
Tiniboy Lancets (36 gauge/70mm) At 36 gauge and just 70mm in length, the Tinyboy lancet is the thinnest and shortest diabetic lancet. Dr. Stanley Kim developed the lancet. Dr. Kim — who has diabetes — wanted a lancet that would be less painful. He currently markets the Tinyboy lancet through …
Read More »Immune System Genes Contribute to Type 1 Diabetes
Immune System Genes Contribute to Type 1 Diabetes: A new study found a link between immune system genes and the risk of Type 1 diabetes. Using a genome-wide association study, the researchers found that a certain group of genes that react in response to viral infections were present in both …
Read More »Use of Diabetes Pills Up, Insulin Use Down
Use of Diabetes Pills Up, Insulin Use Down: The proportion of Americans reporting treatment for diabetes who took oral medications to treat their condition increased from 60% in 1997 to 77% in 2007, a 28% increase, according to the latest “News and Numbers” from the Agency for Healthcare Research and …
Read More »Once-weekly Exenatide vs. Sitagliptin or Pioglitazone
Once-weekly Exenatide vs. Sitagliptin or Pioglitazone: Long-acting exenatide lowered glycosylated hemoglobin levels more than the other two drugs did. After 26 weeks, exenatide lowered the mean HbA1c level significantly more than either sitagliptin or pioglitazone (–1.5% vs. –0.9% and –1.2%). Patients who received exenatide also lost significantly more weight than …
Read More »Blood Test Anticipates Diabetes 10 Years in Advance
A blood test that could predict those at risk of getting diabetes 10 years earlier than current diagnosis has been developed by scientists….
Read More »Gel Technology Utilized in New Artificial Pancreas
A researcher has developed an artificial pancreas that she says could revolutionize the treatment of diabetes….
Read More »Two Year Study: Low-carbohydrate vs. Low-fat Diets
In most previous studies of low-carbohydrate versus low-fat diets, investigators have focused on short-term weight-loss results. U.S. researchers now report results of a 2-year study….
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.